What is Haemonetics's D&A?

Haemonetics (HAE) reported D&A of $27.32M in Q1 2026.

How has Haemonetics's D&A changed year-over-year?

Haemonetics's D&A decreased by 3.2% year-over-year, from $28.21M to $27.32M.

What is the long-term trend for Haemonetics's D&A?

Over 4 years (2022 to 2026), Haemonetics's D&A has grown at a 16.5% compound annual growth rate (CAGR), from $60.74M to $111.72M.

Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.

Haemonetics HAE D&A

D&A at other companies

TFX

TeleflexTFX

$53.74M+39.2%

MedtronicMDT

$716M-14.8%

Merit Medical SystemsMMSI

$30.5M+4.1%

Baxter InternationalBAX

$237M-4.0%

GE HealthCare TechnologiesGEHC

——

SolventumSOLV

——

Segments

By segment

See full

Hospital products and services$14.09M-4.9%

Plasma products and services$11.53M-4.4%

Blood Center products and services$1.77M-17.5%

Other financials

Income statement

See full

Revenue$346.4M+4.8%

Gross profit$198.2M+2.7%

Operating income$67.4M+14.2%

Net income$44.7M+19.3%

EPS (diluted)$0.95+28.4%

Balance sheet

See full

Cash & equivalents$245.4M-20.0%

Total debt$1.3B-0.7%

Total equity$796.3M-3.0%

Total assets$2.4B-2.2%

Cash flow

See full

Operating cash flow$70.9M-39.1%

CapEx$17.7M+12.9%

Free cash flow$53.3M-47.2%

Valuation

See full

Market cap$3.31B-18.0%

Profitability

See full

Gross margin59%+4.0pp

Operating margin19%+5.9pp

Net margin13.3%+3.8pp

FCF margin19.5%+9.1pp

Returns & leverage

See full

Return on equity19.3%+5.2pp

Debt / equity1.6×0.0×

Current ratio3×+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Haemonetics's D&A?: Haemonetics (HAE) reported D&A of $27.32M in Q1 2026.
How has Haemonetics's D&A changed year-over-year?: Haemonetics's D&A decreased by 3.2% year-over-year, from $28.21M to $27.32M.
What is the long-term trend for Haemonetics's D&A?: Over 4 years (2022 to 2026), Haemonetics's D&A has grown at a 16.5% compound annual growth rate (CAGR), from $60.74M to $111.72M.
What does D&A mean?: Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.